Core Insights - Kyntra Bio, formerly known as FibroGen, is actively participating in investor conferences to engage with potential investors and stakeholders [1][2]. Group 1: Investor Conferences - Kyntra Bio will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 2:40-3:10 PM ET in a virtual format [1]. - The company will also present at the Leerink Global Healthcare Conference on March 11, 2026, from 2:20-2:50 PM ET in Miami, FL [1]. - Management will be available for one-on-one meetings during these conferences, and interested investors are encouraged to reach out for scheduling [1]. Group 2: Company Overview - Kyntra Bio is focused on developing novel therapies in oncology and rare diseases, with its lead product, Roxadustat (EVRENZO™), approved in multiple countries for treating anemia in chronic kidney disease patients [2]. - The company is evaluating a Phase 3 trial for Roxadustat in treating anemia associated with lower-risk myelodysplastic syndromes in the U.S. [2]. - Kyntra Bio is also developing FG-3246, a first-in-class antibody-drug conjugate targeting CD46, currently in Phase 2 for metastatic castration-resistant prostate cancer, along with FG-3180, a CD46-targeted PET biomarker [2].

Company Announcement - FibroGen, Inc. will attend and present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, NY [1] - CEO Thane Wettig will deliver a presentation on September 9 at 12:00 PM ET at the Lotte New York Palace Hotel, with a live webcast available [1] Investor Engagement - The management team will be available for one-on-one meetings during the conference, and interested investors should contact their representative at H.C. Wainwright [2] - A replay of the presentation will be posted on the FibroGen website for 90 days after the event [2] Company Overview - FibroGen is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia [3] - Roxadustat (EVRENZO™) is approved in multiple regions, including China, Europe, and Japan, for treating anemia in chronic kidney disease patients [3] - The company is evaluating a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. [3] - FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46, is in development for metastatic castration-resistant prostate cancer, along with FG-3180, a CD46-targeted PET biomarker [3]

Core Viewpoint - The sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited has been approved by the China State Administration for Market Regulation and is expected to close in the third quarter of 2025 [1][2]. Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer biology and anemia [3]. - Roxadustat (EVRENZO™) is approved in multiple regions, including China, Europe, and Japan, for treating anemia in chronic kidney disease (CKD) patients [3]. - The company is evaluating a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. [3]. - FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46, is in development for metastatic castration-resistant prostate cancer, along with FG-3180, a CD46-targeted PET biomarker [3].